Eur Rev Med Pharmacol Sci 2019; 23 (20): 8823-8832
DOI: 10.26355/eurrev_201910_19277

MicroRNA-361-5p suppresses the tumorigenesis of hepatocellular carcinoma through targeting WT1 and suppressing WNT/β-cadherin pathway

Y. Cheng, L. Qiu, G.-L. He, L. Cai, B.-J. Peng, Y.-L. Cao, M.-X. Pan

Second Department of Hepatobiliary Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China. pmxwxy@sohu.com


OBJECTIVE: MicroRNA-361-5p (miR-361-5p) has been found to be involved in the pathogenesis of several human cancers. However, the specific role of miR-361-5p is still unclear in hepatocellular carcinoma (HCC). Therefore, this study was designed to elucidate the function of miR-361-5p in HCC.

PATIENTS AND METHODS: The expression levels of miR-361-5p and Wilms’ tumor-1 (WT1) were detected by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) assay. Moreover, the function of miR-361-5p was examined through Cell Counting Kit-8 (CCK-8) and transwell assays. The protein expressions were examined via Western blot analysis and immunocytochemical assay. Tumor growth of HCC was observed via xenograft tumor formation assay. The relationship between miR-361-5p and WT1 was verified by the Dual-Luciferase assay.

RESULTS: Downregulation of miR-361-5p was identified in HCC, which predicted a worse prognosis in HCC patients. Furthermore, it was found that miR-361-5p suppressed cell proliferation, migration, and invasion in HCC by inhibiting WT1. MiR-361-5p also inhibited tumor growth of HCC. Besides that, miR-361-5p suppressed EMT and negatively activated the WNT/β-cadherin pathway in HCC.

CONCLUSIONS: MiR-361-5p suppressed tumorigenesis of HCC by targeting WT1 and inactivating the WNT/β-cadherin pathway.

Free PDF Download

To cite this article

Y. Cheng, L. Qiu, G.-L. He, L. Cai, B.-J. Peng, Y.-L. Cao, M.-X. Pan
MicroRNA-361-5p suppresses the tumorigenesis of hepatocellular carcinoma through targeting WT1 and suppressing WNT/β-cadherin pathway

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 20
Pages: 8823-8832
DOI: 10.26355/eurrev_201910_19277